MIFH
HRTX icon

Migdal Insurance & Financial Holdings’s Heron Therapeutics HRTX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$3K – 625
2022
Q1 		$3K Sell
500
-1,711
-77% -$12.5K ﹤0.01% 585
2021
Q4 		$21K Sell
2,211
-1,209
-35% -$12.3K ﹤0.01% 556
2021
Q3 		$37K Buy
+3,420
New +$41.6K ﹤0.01% 492

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Migdal Insurance & Financial Holdings's HRTX Position: Q2 2022 in Review

Migdal Insurance & Financial Holdings sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 500 shares — an estimated $3K sold.

Migdal Insurance & Financial Holdings first reported a position in HRTX in Q3 2021 and held it in 3 quarters. The position peaked at $37K in Q3 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 500 Heron Therapeutics shares in Q2 2022, an estimated $3K.
  • Migdal Insurance & Financial Holdings first reported a position in Heron Therapeutics in Q3 2021 and held it in 3 quarters.
  • Migdal Insurance & Financial Holdings's Heron Therapeutics position peaked at $37K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2022, filed 10 Aug 2022.